Un nou capitol în oncologia din România: MagnaPharm și Laboratoires Pierre Fabre anunță disponibilitatea a două terapii țintite pentru pacienții din România

MagnaPharm and Laboratoires Pierre Fabre have launched two targeted therapies in Romania, enhancing treatment options for patients with BRAF mutation cancers. Encorafenib and binimetinib are oral therapies that target the MAPK signaling pathway, crucial for tumor growth. These therapies are part of a long-standing collaboration aimed at improving oncology care in Romania, where cancer remains a significant public health challenge. International studies have shown the effectiveness of this combination in various cancers, including melanoma and colorectal cancer.